Every material Form 8-K Viatris has filed with the SEC since December 06, 2024, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Viatris reported third-quarter 2026 total revenues of $3.75 billion and a U.S. GAAP net loss of $325 million alongside adjusted EBITDA of $1.20 billion. The company raised its full-year 2026 financial guidance midpoints across all metrics and announced plans to acquire Pacira BioSciences for $1.65 billion. Shareholders also benefited from $717 million in year-to-date capital returns, including share repurchases.
Total revenues were $3.75 billion in the third quarter of 2026, matching the prior-year period.
U.S. GAAP net loss widened to $325 million from $128 million in the third quarter of 2025.
Adjusted EBITDA reached $1.20 billion, up 4% on a reported basis from the prior-year period.
The company agreed to acquire Pacira BioSciences for $36.50 per share in cash, representing an equity value of $1.65 billion.
Viatris signed a merger agreement on October 8, 2026 to acquire Pacira BioSciences through a cash tender offer at $36.50 per share, an aggregate equity value of $1.65 billion. Viatris said it expects to fund the deal primarily from excess cash, with the rest from short-term borrowings, and expects it to be immediately accretive to its financial guidance metrics and to close by the end of 2026. The deal is a large acquisition that would add Pacira's marketed EXPAREL and ZILRETTA products to Viatris.
Offer price of $36.50 per share in cash; aggregate equity value of $1.65 billion per the joint press release.
Pacira generated approximately $746 million in total revenue and $177 million in adjusted EBITDA for the twelve months ended June 30, 2026.
Completion requires a majority of Pacira shares tendered; the offer is open for 10 business days, and the merger agreement's outside date is April 8, 2027.
Pacira would pay Viatris a $62 million termination fee under specified circumstances, including a Superior Offer.
Viatris reported second-quarter 2026 results with total revenues of $3.8 billion, up 5% on a reported basis, and adjusted EBITDA of $1.2 billion, up 10%. A U.S. GAAP net loss of $119 million was driven mainly by a non-cash charge of $177.8 million tied to the planned sale of Tyrvaya product rights, and the company raised the midpoints of its 2026 guidance for all metrics.
Total revenues $3.8 billion, up 5% reported and 3.5% operationally versus second-quarter 2025; adjusted EPS $0.69, up 11% reported
U.S. GAAP net loss $119 million, or $(0.10) per share, versus a net loss of $5 million a year earlier, mainly from a $177.8 million non-cash Tyrvaya charge
2026 guidance midpoints raised: total revenues to $14.75 billion from $14.70 billion, adjusted EBITDA to $4.4 billion from $4.3 billion, adjusted EPS to $2.52 from $2.40
Returned approximately $550 million to shareholders through August 5, 2026, including about $270 million in share repurchases; about $730 million remains under the buyback program
Viatris entered into an amended and restated term loan credit agreement on July 1, 2026, providing a ¥40 billion senior unsecured term loan facility with Mizuho Bank, Ltd. as administrative agent. The filing says proceeds will be used in part to repay the prior ¥40 billion unsecured term loan dated July 1, 2021, so the facility replaces existing debt of the same stated amount rather than adding a new borrowing of that size.
Facility amount is ¥40 billion, the same principal as the prior term loan dated July 1, 2021, which the proceeds are partly used to repay.
Interest is set at the TIBO Rate plus 1.10% per annum initially, with the margin able to change based on Viatris's credit ratings from S&P Global Ratings, Moody's and Fitch.
Borrowings are due three years from the July 1, 2026 Closing Date and include a leverage ratio covenant of no greater than 3.75 to 1.00 at each fiscal quarter end.
Mylan Inc., Utah Acquisition Sub Inc. and Mylan II B.V. guarantee the facility as of the Closing Date.
On June 17, 2026, Viatris completed a public offering of €650 million of 4.250% senior unsecured notes due June 17, 2033. The company plans to use the proceeds mainly to repay revolving credit facility borrowings tied to the June 2026 maturity of $1.675 billion of 3.950% notes, with any remainder used to replenish cash. For shareholders, the filing shows the company refinancing a maturing debt obligation with new long-term debt.
Offering size: €650 million aggregate principal amount of 4.250% senior notes due June 17, 2033
Interest is payable annually starting June 17, 2027; notes are guaranteed by Mylan Inc., Mylan II B.V. and Utah Acquisition Sub Inc.
Proceeds intended first to repay revolver borrowings tied to the repayment of the entire $1.675 billion 3.950% notes due 2026
If a change of control event occurs, Viatris must offer to buy the notes at 101% of principal plus accrued interest
Viatris reported first-quarter 2026 total revenues of $3.5 billion, up 8% on a reported basis and 3% operationally, with U.S. GAAP net earnings of $176 million compared with a $3.0 billion net loss a year earlier. The company reaffirmed its 2026 guidance, including adjusted EPS of $2.33 to $2.47, which matters to shareholders because the quarter's profit figures were compared against a year-earlier period that included a $2.9 billion goodwill impairment.
Adjusted EPS was $0.59, up 18% on a reported basis and 14% operationally, versus $0.50 a year earlier.
U.S. GAAP net earnings were $176.4 million, helped by a $423.7 million income tax benefit; the loss before income taxes was $247.3 million.
U.S. GAAP net cash provided by operating activities was $388.3 million, down 27%, and free cash flow was $348.4 million, down 29%.
2026 guidance reaffirmed: total revenues of $14.45 billion to $14.95 billion and adjusted EBITDA of $4.15 billion to $4.45 billion.
Viatris said Chief Financial Officer Doretta Mistras will leave the company to pursue another professional opportunity, effective May 8, 2026, and will stay on until May 22, 2026 for transition. Chief Accounting Officer and Corporate Controller Paul Campbell will serve as interim CFO starting May 8 while the board searches for a permanent CFO, and the company will report first-quarter 2026 results on May 7.
Mistras ceases to serve as CFO effective May 8, 2026, and remains employed until May 22, 2026 for transition purposes.
Paul Campbell, age 59, is appointed interim CFO effective May 8, 2026, and continues as Chief Accounting Officer and Corporate Controller.
Mistras will not receive severance or equity vesting, but is eligible for a pro rata 2026 bonus based on actual company performance, not to exceed target.
The company will release first-quarter 2026 financial results on May 7, 2026, with a conference call at 8:30 a.m. ET.
Viatris reported fourth-quarter 2025 total revenues of $3.7 billion, up 5% from a year earlier, and adjusted EPS of $0.57, up 6%, while full-year 2025 revenues fell 3% to $14.3 billion and adjusted EPS fell 11% to $2.35. The company also completed its enterprise-wide strategic review, which includes a global workforce reduction of up to approximately 10% and pre-tax restructuring charges of $700 million to $850 million, with estimated annual savings of $600 million to $700 million once fully implemented.
Q4 2025: total revenues $3.7 billion (up 5%); U.S. GAAP net loss $340 million, compared with $517 million a year earlier
Full-year 2025: total revenues $14.3 billion (down 3%); U.S. GAAP net loss $3.5 billion, including a $2.9 billion goodwill impairment charge
2026 guidance: total revenues $14.45 billion to $14.95 billion; adjusted EPS $2.33 to $2.47
Restructuring charges of $700 million to $850 million, mostly cash, to be completed primarily over the next three years; a mid-February 2026 fire at the Nashik, India plant has suspended manufacturing there, with operations expected to resu
Viatris said Chief Legal Officer Brian Roman will leave the role effective February 9, 2026, and remain an employee until April 1, 2026 for transitional purposes. Matthew Maletta, formerly Executive Vice President, Chief Legal Officer and Secretary at Endo, Inc., will become Chief Legal Officer on February 9, 2026. The filing describes a planned leadership handover in a senior legal role rather than a change in company operations or financial results.
Brian Roman ceases to serve as Chief Legal Officer effective February 9, 2026, and remains an employee until April 1, 2026
Roman may receive separation payments equal to base salary plus target bonus, plus a pro rata bonus for 2026, subject to a customary release of claims
Matthew Maletta joins as Chief Legal Officer on February 9, 2026
Maletta served at Endo, Inc. from 2015 to 2025 as Executive Vice President, Chief Legal Officer and Secretary
Viatris reported third-quarter 2025 total revenues of $3.8 billion, flat on a reported basis, and a U.S. GAAP net loss of $128 million, compared with net earnings of $95 million a year earlier. The company attributed the loss mainly to a reduction in the fair value of its Biocon Biologics preferred shares and higher income tax expense, and it raised and narrowed its 2025 guidance ranges for total revenues, adjusted EBITDA and adjusted EPS.
Q3 2025 total revenues were $3.8 billion, flat reported and down 1% on a divestiture-adjusted operational basis; the estimated Indore Impact was about $100 million in the quarter.
Q3 2025 U.S. GAAP net loss was $(128) million, or $(0.11) per share, versus net earnings of $95 million, or $0.08 per share, in Q3 2024; adjusted EPS was $0.67, down 11% reported.
2025 guidance now shows total revenues of $13.9 billion to $14.3 billion (previously $13.5 billion to $14.0 billion) and adjusted EPS of $2.25 to $2.35 (previously $2.16 to $2.30).
Year-to-date, Viatris returned more than $920 million to shareholders, including $500 million in share repurchases.
Viatris reported second quarter 2025 results with total revenues of $3.6 billion, down 6% from a year earlier, and adjusted EPS of $0.62, down 10%. The company reaffirmed its 2025 guidance ranges and said it expects to land in the top half of the range for total revenues and adjusted EPS, which matters to shareholders because the company attributes the declines mainly to the Indore Impact.
Q2 2025 total revenues were $3.6 billion, down 6% reported and down 2% on a divestiture-adjusted operational basis versus Q2 2024.
U.S. GAAP net loss narrowed to $(5) million from $(326) million a year earlier; adjusted EPS was $0.62 versus $0.69.
The estimated Indore Impact reduced Q2 2025 total revenues by approximately $160 million.
2025 guidance reaffirmed: total revenues $13,500 million to $14,000 million and adjusted EPS $2.16 to $2.30; year-to-date capital returned exceeded $630 million, including $350 million in share repurchases.
Viatris expanded its Board from 14 to 15 members and appointed David Simmons as an independent director, effective immediately, with a term expiring at the 2025 annual meeting. The company has not yet named committee assignments, which it says it will disclose in a later amendment to this filing.
Board increased from 14 to 15 members; David Simmons appointed on August 4, 2025, with a term ending at the 2025 annual meeting
Simmons is the CEO of Caliber Holdings Corporation and previously served as Chairman and CEO of PPD, Inc.
He spent more than 15 years at Pfizer Inc., including overseeing its Established Products Unit
Simmons will receive compensation consistent with other non-employee directors, and the company has an indemnification agreement with him
Viatris reported first quarter 2025 total revenues of $3.3 billion, down 11% from a year earlier, and a U.S. GAAP net loss of $3.0 billion, driven by a non-cash goodwill impairment charge of $2.9 billion. Adjusted EPS was $0.50, down 25%, and the company reaffirmed its 2025 outlook, including adjusted EPS guidance of $2.16 to $2.30. The filing also says the company has returned more than $450 million to shareholders year to date.
Total revenues $3.3 billion (down 11% reported; down 2% divestiture-adjusted operational basis); Indore Impact estimated at approximately $140 million in the quarter
U.S. GAAP net loss $(3.0) billion, or $(2.55) per share, versus net earnings of $114 million, or $0.09 per share, a year earlier
Adjusted EPS $0.50 versus $0.67 a year earlier; adjusted EBITDA $923.5 million, down 23%
2025 guidance reaffirmed; share repurchases of $500 million to $650 million expected in 2025
Viatris appointed Frank D'Amelio, former Pfizer CFO, and Michael Severino, M.D., former AbbVie executive, to its Board of Directors effective May 5, 2025, expanding the Board from 12 to 14 seats. Directors Rajiv Malik and Harry Korman will retire at the end of their current terms in December 2025, following the 2025 Annual Meeting. The filing reports no financial results, and it describes a Board change rather than a financial event.
Board size increased from 12 to 14 directors, effective May 5, 2025
Frank D'Amelio joins the Finance Committee; Michael Severino joins the Science and Technology Committee
Rajiv Malik and Harry Korman will not stand for re-election at the 2025 Annual Meeting and will retire at the end of their current terms
Retirements were not the result of any disagreement with the company on operations, policies, or practices
On February 27, 2025, Viatris reported fourth quarter and full-year 2024 results and issued 2025 guidance. Full-year 2024 total revenues were $14.7 billion, down 5% as reported, and the U.S. GAAP net loss was $634.2 million, compared with net earnings of $54.7 million in 2023. The company guided 2025 total revenues to $13.5 billion to $14.0 billion and adjusted EPS to $2.12 to $2.26, and said an FDA import alert at its Indore facility is expected to reduce 2025 total revenues by about $500 million and adjusted EBITDA by about $385 million.
Full-year 2024 total revenues were $14.7 billion, down 5% as reported; adjusted EPS was $2.65, versus $2.93 in 2023.
U.S. GAAP net loss was $(634.2) million for 2024, compared with net earnings of $54.7 million in 2023.
2025 guidance: total revenues of $13.5 billion to $14.0 billion and adjusted EPS of $2.12 to $2.26.
Indore facility impact is estimated at about $500 million to 2025 total revenues and about $385 million to adjusted EBITDA; the company plans $500 million to $650 million in 2025 share repurchases.
At its December 6, 2024 annual meeting, Viatris shareholders did not approve, on an advisory basis, the 2023 compensation of its named executive officers, with 49.23% of votes in favor. Shareholders approved an amendment adding 49,000,000 shares to the 2020 Stock Incentive Plan and elected all twelve director nominees, so the pay vote result is the main governance signal for holders.
Advisory vote on 2023 executive pay not approved: 445,035,979 for and 458,870,163 against, with 49.23% in favor, missing approval by less than 0.80%.
2020 Stock Incentive Plan amendment approved (872,421,538 for, 31,280,303 against), adding 49,000,000 shares and eliminating an exception to the 12-month minimum vesting requirement for certain ad hoc awards.
All twelve director nominees elected to serve until the 2025 annual meeting; Deloitte & Touche LLP ratified as auditor for fiscal year ending December 31, 2024.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Viatris filing is on SEC EDGAR ↗. 8-K briefs of other companies →